These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 12199627)

  • 1. Targeting vascular endothelial growth factor in colorectal cancer.
    Berlin JD
    Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):13-5. PubMed ID: 12199627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.
    Kabbinavar F; Irl C; Zurlo A; Hurwitz H
    Oncology; 2008; 75(3-4):215-23. PubMed ID: 18852492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
    Kabbinavar FF; Schulz J; McCleod M; Patel T; Hamm JT; Hecht JR; Mass R; Perrou B; Nelson B; Novotny WF
    J Clin Oncol; 2005 Jun; 23(16):3697-705. PubMed ID: 15738537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
    Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
    J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of bevacizumab as first-line therapy for colon cancer.
    Marshall J
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S43-7. PubMed ID: 16399431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
    J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
    Lockhart AC; Cropp GF; Berlin JD; Donnelly E; Schumaker RD; Schaaf LJ; Hande KR; Fleischer AC; Hannah AL; Rothenberg ML
    Am J Clin Oncol; 2006 Apr; 29(2):109-15. PubMed ID: 16601426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
    Prescrire Int; 2006 Jun; 15(83):94-7. PubMed ID: 16764097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.
    Hurwitz H
    Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S62-8. PubMed ID: 15479481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adjuvant and palliative anticancer treatment of colon carcinoma in 2004].
    Medinger M; Steinbild S; Mross K
    Praxis (Bern 1994); 2004 Sep; 93(40):1633-44. PubMed ID: 15495753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
    Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
    Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer.
    Clin Colorectal Cancer; 2003 Aug; 3(2):85-8. PubMed ID: 12952562
    [No Abstract]   [Full Text] [Related]  

  • 14. Bevacizumab for advanced colorectal cancer.
    Hadj Tahar A
    Issues Emerg Health Technol; 2004 Dec; (63):1-4. PubMed ID: 15612152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
    Hurwitz H; Kabbinavar F
    Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
    Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
    Grothey A; Hedrick EE; Mass RD; Sarkar S; Suzuki S; Ramanathan RK; Hurwitz HI; Goldberg RM; Sargent DJ
    J Clin Oncol; 2008 Jan; 26(2):183-9. PubMed ID: 18182660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biotherapy in colorectal cancer].
    Des Guetz G
    J Chir (Paris); 2005; 142(5):291-6. PubMed ID: 16292207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
    Cetin B; Kaplan MA; Berk V; Ozturk SC; Benekli M; Isıkdogan A; Ozkan M; Coskun U; Buyukberber S
    Asian Pac J Cancer Prev; 2012; 13(3):1059-63. PubMed ID: 22631638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.